AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23213075
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (SMT)
Trial: 19075102
Drug: simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg/d
Trial: 19075102
Drug: simvastatin/ezetimibe 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin/ezetimibe 10/10 mg/d
Trial: 17824295
Drug: Carni Q-gel
RxNorm normalized name: Carni Q-Gel Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carni Q-gel (2250 mg/d L-carnitine and 270 mg/d hydrosoluble ubiquinol) for 12 weeks
Trial: 17824295
Drug: Carni Q-gel
RxNorm normalized name: Carni Q-Gel Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carni Q-gel
Trial: 9793589
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 750 mg/5 mL with normal breakfast (fat content 21 g)
Trial: 9793589
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 750 mg/5 mL with Sustacal Plus (fat content 28 g)
Trial: 9793589
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 750 mg/5 mL fasting
Trial: 408142
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose on day 4 (n = 6)
Trial: 408142
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg glucagon with glucose load on day 4 (n = 5)
Trial: 408142
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glucagon with glucose load on day 4 (n = 6)
Trial: 408142
Drug: Glucagon administered
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon administered 24 h after glucose load (n = 6)
Trial: 26051429
Drug: Olive leaf
RxNorm normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive leaf extract (OLE) (51 mg oleuropein; 10 mg HT)
Trial: 21083582
Drug: Itopride 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 50 mg
Trial: 21083582
Drug: Itopride 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 100 mg
Trial: 19690227
Drug: On-demand use
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand use of antibiotics
Trial: 17224857
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg drospirenone/1 mg estradiol (DRSP/E2)
Trial: 11885213
Drug: Outpatient women-centered
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient women-centered substance abuse treatment program
Trial: 9782691
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (treatment group)
Trial: 7869251
Drug: L-NMMA (nitric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (nitric oxide synthase blocker)
Trial: 7869251
Drug: Atropine +
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine + L-NMMA
Trial: 7869251
Drug: Control (contralateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (contralateral forearm without treatment)
Trial: 31102326
Drug: Glimepiride (1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1-3 mg/day)
Trial: 31129812
Drug: L-selenomethionine (L-Se-Met)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-selenomethionine (L-Se-Met) 83 mcg/day
Trial: 26056515
Drug: Regular beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular beer (up to 660 ml) followed by water ad-libitum (BW)
Trial: 21659972
Drug: Risedronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (35 mg once a week) + 600 mg calcium + 400 IU vitamin D
Trial: 21659972
Drug: Control (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (600 mg calcium + 400 IU vitamin D)
Trial: 17448262
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone (GnRH) analogues
Trial: 12969167
Drug: Fosinopril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril, 10 mg/day
Trial: 1333909
Drug: Suspension injection
RxNorm normalized name: Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension injection alone (A, n = 54)
Trial: 1333909
Drug: Suspension injection
RxNorm normalized name: Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension injection + TAE using gelatin sponge (B, n = 29)
Trial: 1333909
Drug: TAE followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAE followed by suspension injection (C, n = 34)
Trial: 6385745
Drug: Optimal oral
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal oral nutrition
Trial: 29324495
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (2 mg/kg for 15 minutes followed by 2 mg/kg/h)
Trial: 29324495
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (20 mg/kg over 15 minutes followed by 20 mg/kg/h)
Trial: 26792372
Drug: Intravenous Zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous Zoledronic acid
Trial: 12575396
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) combined with captopril (CAP)
Trial: 2439255
Drug: Intraoperative colloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative colloids (0.5 g/kg)
Trial: 29101402
Drug: Sertraline (n=102)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (n=102) at an initial dose of 50 mg/d, escalated to a maximum of 200 mg/d for 12 weeks
Trial: 29101402
Drug: Sertraline (n=102)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (n=102)
Trial: 23293335
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (1 infusion)
Trial: 23293335
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (3 infusions)
Trial: 17898344
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment for up to 14 weeks
Trial: 18288090
Drug: Next-step treatment
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next-step treatment after citalopram
Trial: 18288090
Drug: Third-step treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Third-step treatment among those with unsatisfactory benefit to citalopram and one next-step pharmacotherapy
Trial: 16547529
Drug: Broad-based immunomodulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-based immunomodulatory agents (e.g. intravenous immunoglobulin, thalidomide, pentoxifylline)
Trial: 1439112
Drug: Thymostimulin (Tp-1)
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (Tp-1) treatment
Trial: 24336664
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group therapy (10 sessions)
Trial: 10673735
Drug: Newer antihypertensive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antihypertensive agents (amlodipine and perindopril)
Trial: 10673735
Drug: Older antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older antihypertensive agents (bendroflumethiazide and atenolol)
Trial: 9104123
Drug: Cairwave Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cairwave Therapy System
Trial: 31584782
Drug: Halobetasol 0.01%
RxNorm normalized name: HALOBETASOL 0.01%/TAZAROTENE 0.045% LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol 0.01% lotion
Trial: 27181998
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg once daily (S100)
Trial: 27181998
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily (M1000)
Trial: 27181998
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice daily (M1700)
Trial: 27181998
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg twice daily plus Metformin 500 mg twice daily (S100/M1000)
Trial: 27181998
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg twice daily plus Metformin 850 mg twice daily (S100/M1700)
Trial: 27181998
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin groups
Trial: 12618970
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg azithromycin once daily for 3 days
Trial: 12618970
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg erythromycin stearate every 6 hours for 3 days
Trial: 6303001
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg propranolol (Dociton)
Trial: 6303001
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg metoprolol (Beloc)
Trial: 31418425
Drug: Call center
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Call center intervention providing information about MR medications
Trial: 19299533
Drug: Tedisamil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil (100 mg bid)
Trial: 19299533
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tedisamil and verapamil
Trial: 19299533
Drug: Verapamil (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (180 mg bid)
Trial: 19299533
Drug: Tedisamil and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil and verapamil combination
Trial: 19299533
Drug: Verapamil and
RxNorm normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil and tedisamil combination
Trial: 12113382
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol 9 microg twice daily
Trial: 14682413
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline 400 mg once daily
Trial: 9925123
Drug: High-fiber meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber meal (15.7 g fiber) containing barley pasta enriched with beta-glucan
Trial: 9925123
Drug: Low-fiber meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber meal (5.0 g fiber) containing pasta made with wheat flour
Trial: 7672999
Drug: Intramuscular 800
RxNorm normalized name: Peptimax 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 800 mg (5 ml) human immunoglobulin (1x/week)
Trial: 7672999
Drug: Panthenol (4x10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panthenol (4x10 ml/day) and nystatin (4 x 1 ml/day)
Trial: 7234648
Drug: Diltiazem (D)
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem (D) 240 mg
Trial: 31446157
Drug: Yohimbine (alpha2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (alpha2-receptor antagonist)
Trial: 24079281
Drug: rosuvastatin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (maximum dose of 10 mg for <10 years, 20 mg for older children)
Trial: 22140514
Drug: Internet CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet CBT plus weekly telephone follow‐up
Trial: 22140514
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone follow‐up only
Trial: 15569112
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg intravenously
Trial: 9142772
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dosing (SDD) of aminoglycosides
Trial: 9142772
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily dosing of aminoglycosides
Trial: 1430080
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg TB
Trial: 1430080
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg TB
Trial: 21689179
Drug: Analgesics used
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics used
Trial: 10327526
Drug: Randomization-based tests
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization-based tests for no treatment effect
Trial: 8890801
Drug: Aspirin (medication)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (medication)
Trial: 1676361
Drug: Antacids and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids and/or histamine‐2‐receptor antagonists
Trial: 1676361
Drug: Stress ulcer
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stress ulcer prophylactic therapy titrated to achieve a gastric pH of 3.5 or greater
Trial: 21115191
Drug: 60 Second
RxNorm normalized name: 60 Second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 Second Taste Gel
Trial: 21115191
Drug: pH7 Gel
RxNorm normalized name: Sodium Fluoride 9.05 mg in 1 g BUCCAL GEL [pH7 Gel Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH7 Gel (neutral fluoride agent)
Trial: 19900941
Drug: Single-dose cruciferous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cruciferous diet in GSTM1-null/GSTT1-null individuals
Trial: 19900941
Drug: Double-dose cruciferous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose cruciferous diet in GSTM1-null/GSTT1-null men
Trial: 19900941
Drug: Double-dose cruciferous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose cruciferous diet in GSTM1+/GSTT1+ men
Trial: 16870070
Drug: Bisoprolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol plus magnesium (Mg)
Trial: 16870070
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no combined study medication)
Trial: 12825002
Drug: Thyroid-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid-releasing hormone (TRH)
Trial: 10427126
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) combined with transcatheter arterial embolization (TAE) and percutaneous ethanol injection (PEI)
Trial: 7943099
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (60 mg/day)
Trial: 30575484
Drug: sorafenib (400‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib (400‐mg tablet once daily)
Trial: 22402913
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (No Treatment)
Trial: 20197017
Drug: Schisandra sphenanthera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group A (same dose of Tac)
Trial: 20197017
Drug: Schisandra sphenanthera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group B (lower dose of Tac)
Trial: 20197017
Drug: Schisandra sphenanthera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac)
Trial: 2279542
Drug: alpha interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by splenectomy
Trial: 2279542
Drug: alpha interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by observation
Trial: 7002563
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) intravenous infusion at doses up to 4 ng/kg per min
Trial: 7002563
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) intravenous infusion at 4 ng/kg per min
Trial: 7002563
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) intravenous infusion
Trial: 27182005
Drug: Omarigliptin 5-100
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin 5-100 mg single dose
Trial: 27182005
Drug: Omarigliptin 1-50
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin 1-50 mg multiple once-weekly dose
Trial: 27182005
Drug: Omarigliptin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omarigliptin (various doses)
Trial: 23394494
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol (group T)
Trial: 21105991
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC)
Trial: 19671802
Drug: Ustekinumab (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (45 mg for patients <100 kg or 90 mg for patients >100 kg, administered subcutaneously; second dose at 4 weeks, then every 8-12 weeks based on response)
Trial: 18038253
Drug: PRO 160/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO 160/120 (160 mg Sabal fruit extract WS 1473 and 120 mg Urtica root extract WS 1031 per capsule, 2 x 1 capsule/day)
Trial: 15506025
Drug: Cerec crowns
RxNorm normalized name: ceric oxide
DrugBank: Cerium dioxide (DB18493)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerec crowns with reduced stump preparations
Trial: 10861146
Drug: Lidocaine treatment
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine treatment group
Trial: 10861146
Drug: Bupivacaine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine treatment group
Trial: 9092954
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at daily target dosages of 200-1,000 mg/day
Trial: 23965645
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg co-administered with simvastatin
Trial: 23965645
Drug: Optimal simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimal simvastatin dose
Trial: 20550071
Drug: Automated chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated chest percussion therapy (CPT) for 10 minutes
Trial: 18600390
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interferon-alpha (6 million units daily for 2 weeks, then three times weekly) plus lamivudine (100 mg daily) for 24 weeks followed by lamivudine alone for 28 weeks (n = 30)
Trial: 18600390
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interferon-alpha plus lamivudine
Trial: 18600390
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (n = 34)